Compass <a href="https://laohu8.com/S/LENZ">Therapeutics</a> posts $14.3 million net loss for third quarter 2025
Compass Therapeutics Inc. reported a net loss of $14.3 million for the three months ended September 30, 2025, compared to a net loss of $10.5 million for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $50.8 million, up from $34.3 million in the prior year period. Research and development expenses increased by 44% to $42.3 million for the nine months ended September 30, 2025, primarily due to higher manufacturing and IND-enabling costs related to tovecimig and CTX-10726. Other income decreased by 29% to $3.9 million for the nine months ended September 30, 2025, due to lower interest income from reduced average cash and marketable securities balances. The company has not generated revenue from the sale of products and continues to fund operations primarily through equity securities, with $568 million raised in gross proceeds to date.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-007005), on November 05, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。